Drug & intervention

binimetinib

RxCUI 2049122

Clinical trials22
Recruiting2
Related conditions20
Synonyms1

RxNorm ingredient and formulation relationships

Source-verified product relationships. Every strength, delivery form and RxCUI remains a separate clinical concept.

Loading RxNorm relationships…

Clinical trials

22 shown
Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening TrialNCT05564377 · 2023-04-07
RECRUITING
Testing the Combination of the Anticancer Drugs ZEN003694 and Binimetinib in Patients With Advanced/Metastatic or Unresectable Solid Tumors With RAS Alterations and Triple Negative Breast CancerNCT05111561 · 2022-08-02
RECRUITING
Testing the Use of Fulvestrant and Binimetinib Targeted Treatment for NF1 Mutation in Hormone Receptor-Positive Metastatic Breast Cancer (A ComboMATCH Treatment Trial)NCT05554354 · 2024-09-13
TERMINATED
Binimetinib and Palbociclib Before Surgery for the Treatment of Operable KRAS-Positive Lung, Colorectal, or Pancreatic CancerNCT04870034 · 2024-01-15
WITHDRAWN
A Study to Learn About the Study Medicine Called PF-07799933 in People With Advanced Solid Tumors With BRAF Alterations.NCT05355701 · 2022-07-05
ACTIVE_NOT_RECRUITING
Phase II Study Investigating the Combination of Encorafenib and Binimetinib in BRAF V600E Mutated Chinese Patients With Metastatic Non-Small Cell Lung CancerNCT05195632 · 2022-06-02
ACTIVE_NOT_RECRUITING
Study of Inlexisertib (DCC-3116) in Participants With RAS/MAPK Pathway Mutant Solid TumorsNCT04892017 · 2021-06-15
TERMINATED
PF-07284892 in Participants With Advanced Solid TumorsNCT04800822 · 2021-03-17
TERMINATED
A FIH Study of PF-07284890 in Participants With BRAF V600 Mutant Solid Tumors With and Without Brain InvolvementNCT04543188 · 2021-01-08
TERMINATED
Study of Immunotherapy (Sasanlimab) in Combination With Targeted Therapies in People With Advanced Non-small Cell Lung Cancer (NSCLC) (Landscape 1011 Study)NCT04585815 · 2020-11-10
TERMINATED
Lorlatinib Combinations in Lung CancerNCT04292119 · 2020-05-01
UNKNOWN
Brigatinib and Binimetinib in Treating Patients With Stage IIIB-IV ALK or ROS1-Rearranged Non-small Cell Lung CancerNCT04005144 · 2020-02-25
TERMINATED
Study of Binimetinib in Combination With Pembrolizumab in Advanced Non-Small Cell Lung CancerNCT03991819 · 2019-09-20
ACTIVE_NOT_RECRUITING
Avelumab With Binimetinib, Sacituzumab Govitecan, or Liposomal Doxorubicin in Treating Stage IV or Unresectable, Recurrent Triple Negative Breast CancerNCT03971409 · 2019-07-08
ACTIVE_NOT_RECRUITING
An Open-label Study of Encorafenib + Binimetinib in Patients With BRAFV600-mutant Non-small Cell Lung CancerNCT03915951 · 2019-06-04
COMPLETED
Safety and Efficacy of Pembrolizumab (MK-3475) Plus Binimetinib Alone or Pembrolizumab Plus Chemotherapy With or Without Binimetinib in Metastatic Colorectal Cancer (mCRC) Participants (MK-3475-651/KEYNOTE-651)NCT03374254 · 2018-02-16
COMPLETED
Pembrolizumab and Binimetinib in Treating Patients With Locally Advanced or Metastatic Triple Negative Breast CancerNCT03106415 · 2017-09-27
COMPLETED
Study of Palbociclib in Combination With Binimetinib for Patients With Advanced KRAS Mutant Non-Small Cell Lung CancerNCT03170206 · 2017-05-31
COMPLETED
Binimetinib in Addition to Standard Chemotherapy in KRAS Mutated NSCLC.NCT02964689 · 2017-04-12
COMPLETED
A Phase I/Ib Study of MEK162, a MEK Inhibitor, in Combination With Carboplatin and Pemetrexed in Patients With Non-squamous Carcinoma of the LungNCT02185690 · 2017-03-07
COMPLETED
Binimetinib With Docetaxel in Treating Patients With Previously Treated, Stage IV Non-small Cell Lung CancerNCT02451865 · 2016-06-01
WITHDRAWN
Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)NCT02465060 · 2015-08-17
ACTIVE_NOT_RECRUITING

Conditions being studied

Advanced Malignant Solid Neoplasm3Lung Cancer3Non-Small Cell Lung Cancer3Anatomic Stage IV Breast Cancer AJCC v82Carcinoma, Non-Small-Cell Lung2Colorectal Carcinoma2Glioma2Melanoma2Metastatic HER2-Negative Breast Carcinoma2Metastatic Malignant Solid Neoplasm2Recurrent Breast Carcinoma2Recurrent Malignant Solid Neoplasm2Recurrent Ovarian Carcinoma2Refractory Malignant Solid Neoplasm2Triple-Negative Breast Carcinoma2Unresectable Malignant Solid Neoplasm2Advanced Colorectal Cancer (Part 1)1Advanced Lymphoma1Advanced Non-small Cell Lung Cancer1Advanced Solid Tumor1

Drug identity and terminology: RxNorm. Trial relationships: ClinicalTrials.gov.